Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service lumbar fusion cases in New Mexico: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 4% on average (239 state-years, 2020–2024): a close guide.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 12 | 282 | 40% |
| 2020 | 7 | 239 | 43% |
| 2021 | 8 | 290 | 46% |
| 2022 | 7 | 414 | 50% |
| 2023 | 6 | 263 | 53% |
| 2024 | 8 | 282 | 54% |
| 2025 from claims | – | 175 142–206 | 54% |
| 2026 forecast | – | 175 137–220 | 55% |
| 2027 forecast | – | 176 131–233 | 55% |
| 2028 forecast | – | 177 125–245 | 56% |
| 2029 forecast | – | 178 121–256 | 56% |
| 2030 forecast | – | 180 118–266 | 56% |
Posterolateral, interbody, and anterior lumbar fusion with instrumentation. Professional codes (what the surgeon bills): CPT 22612, 22630, 22633, 22558; the hospital bills MS-DRG 453, 454, 455, 459, 460, 402, 426, 427, 428, 447, 448, 450, 451, 523, 524, 525.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 100% of the cases CMS names in New Mexico; 5 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
In 2025, 66% inpatient hospital, 34% hospital outpatient.
CMS rule changes ahead
From CMS’s OPPS/ASC final rules; the move measured on CMS’s claim summary, nationally, code by code. Medicare only, and not in the projected bars.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| California | 199 | 8,753−1%/yr | −1%/yr | 2.5 | 2% | 9,020 in 2030+0.5%/yr |
| Arizona | 68 | 2,849+1.1%/yr | +1.1%/yr | 3.7 | 2% | 3,400 in 2030+3%/yr |
| Colorado | 67 | 2,336−3.9%/yr | −3.9%/yr | 4.6 | 1% | 2,600 in 2030+1.8%/yr |
| Washington | 49 | 1,995−4.1%/yr | −4.1%/yr | 2.5 | 1% | 1,980 in 2030−0.1%/yr |
| Utah | 27 | 1,165−2.8%/yr | −2.8%/yr | 5.1 | 1% | 1,160 in 2030−0.1%/yr |
| Oregon | 23 | 1,070−2.7%/yr | −2.7%/yr | 2.5 | 2% | 1,000 in 2030−1.2%/yr |
| Nevada | 24 | 953−1.6%/yr | −1.6%/yr | 3.2 | 2% | 760 in 2030−3.7%/yr |
| Idaho | 21 | 882+2.3%/yr | +2.3%/yr | 4.2 | 2% | 1,290 in 2030+6.6%/yr |
| Montana | 16 | 506−1.2%/yr | −1.2%/yr | 2.6 | 0% | 540 in 2030+1.1%/yr |
| Alaska | 7 | 258+4.9%/yr | +4.9%/yr | 2.1 | 0% | 380 in 2030+6.8%/yr |
| Wyoming | 6 | 246−5.5%/yr | −5.5%/yr | 2.2 | 8% | 270 in 2030+1.8%/yr |
| Hawaii | 4 | 124−3.3%/yr | −3.3%/yr | 0.9 | 36% | 150 in 2030+3%/yr |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Decompression & minimally invasive spine | 7 | 250−13%/yr | −13%/yr | 1.00.3× | 0% | 350 in 2030+5.7%/yr |
| Cervical fusion & disc arthroplasty | 2 | 123−6.5%/yr | −6.5%/yr | 0.50.4× | 0% | 250 in 2030+13%/yr |
| Kyphoplasty & vertebroplasty | 1 | 106−5.5%/yr | −5.5%/yr | 0.50.5× | 0% | 90 in 2030−3.6%/yr |
Lumbar fusion in every state, and its device makers · Every procedure market in New Mexico · Every state · Compare with California
Globus Medical leads with 36% of company spending on these surgeons in 2025, +14 pts on 2024.
In 2025, 10 companies reported engagement with New Mexico’s surgeons worth $44K in consulting, speaking, meals and travel tied to these products, about $5,557 per surgeon billing it. Royalties are left out.
FDA, last 12 months: 87 clearances and approvals in the category, 12 recalled product lines. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.